Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Third Cell Therapy For Lymphoma Approved In The US
Executive Summary
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
You may also be interested in...
Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success
Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.
BMS Sighs In Relief As Opdivo Returns To Sales Growth
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.
New Data Brings Yescarta Closer To Blockbuster Territory
Gilead announced positive topline results from the ZUMA-7 trial of Yescarta in second-line large B-cell lymphoma, where the CAR-T would eventually compete with BMS’s Breyanzi and Novartis’ Kymriah.